Literature DB >> 10580795

Role of the cervical lymphatics in the Th2-type hierarchy of CNS immune regulation.

C J Harling-Berg1, T J Park, P M Knopf.   

Abstract

CNS immune regulation is intimately dependent on the dynamics of cerebral extracellular fluid circulation. Animal models indicate that following the introduction of antigen into the CNS, normal circulation of interstitial and cerebrospinal fluids provides the opportunity for (a) delivery of CNS-derived antigen to lymphoid organs, as well as, (b) retention of immunologically significant amounts of antigen within the CNS. Thus, even in the absence of disease, CNS-derived antigen can induce antigen-specific activation of naive lymphocytes in lymphoid organs and specific reactivation of lymphoblasts that have migrated into the CNS. The initial peripheral immune response to CNS-derived antigen is induced in cervical lymph nodes and is characterized by a strong antibody response, no delayed-type hypersensitivity, and only priming for cytotoxic T-cell responses. This Th-2 type hierarchy of immune regulation is reinforced within the antigen-stimulated CNS where specific B lymphoblasts are permitted to develop their effector function but cell-mediated immunity is inhibited. Developing a paradigm for CNS immune regulation is important in understanding how CNS disorders in humans are induced, perpetuated, and may be manipulated.

Entities:  

Mesh:

Year:  1999        PMID: 10580795     DOI: 10.1016/s0165-5728(99)00130-7

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  32 in total

Review 1.  Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

Authors:  Amy B Heimberger; John H Sampson
Journal:  Neuro Oncol       Date:  2010-12-10       Impact factor: 12.300

Review 2.  Failed central nervous system regeneration: a downside of immune privilege?

Authors:  Ingo Bechmann
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

3.  Migration of monocytes after intracerebral injection.

Authors:  Miriam Kaminski; Ingo Bechmann; Jürgen Kiwit; Jana Glumm
Journal:  Cell Adh Migr       Date:  2012-05-01       Impact factor: 3.405

4.  Prediagnostic plasma IgE levels and risk of adult glioma in four prospective cohort studies.

Authors:  Federico C F Calboli; David G Cox; Julie E Buring; J Michael Gaziano; Jing Ma; Meir Stampfer; Walter C Willett; Shelley S Tworoger; David J Hunter; Carlos A Camargo; Dominique S Michaud
Journal:  J Natl Cancer Inst       Date:  2011-10-18       Impact factor: 13.506

5.  Brain granulomas in neurocysticercosis patients are associated with a Th1 and Th2 profile.

Authors:  B I Restrepo; J I Alvarez; J A Castaño; L F Arias; M Restrepo; J Trujillo; C H Colegial; J M Teale
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

6.  Implications of immune system in stroke for novel therapeutic approaches.

Authors:  Aaron A Hall; Keith R Pennypacker
Journal:  Transl Stroke Res       Date:  2010-01-13       Impact factor: 6.829

Review 7.  Immunotherapy for brain cancer: recent progress and future promise.

Authors:  Christopher M Jackson; Michael Lim; Charles G Drake
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

8.  Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model.

Authors:  John R Ohlfest; Brian M Andersen; Adam J Litterman; Junzhe Xia; Christopher A Pennell; Lauryn E Swier; Andres M Salazar; Michael R Olin
Journal:  J Immunol       Date:  2012-12-17       Impact factor: 5.422

9.  CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma.

Authors:  Katherine A Murphy; Jami R Erickson; Charles S Johnson; Charles E Seiler; Jessica Bedi; Peisheng Hu; G Elizabeth Pluhar; Alan L Epstein; John R Ohlfest
Journal:  J Immunol       Date:  2013-11-29       Impact factor: 5.422

Review 10.  Dendritic cell-based immunotherapy for malignant glioma.

Authors:  Jin-Hai Gu; Gang Li
Journal:  Neurosci Bull       Date:  2008-02       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.